

Review

Open Access

## Vorinostat in solid and hematologic malignancies

David Siegel\*<sup>1</sup>, Mohamad Hussein<sup>2</sup>, Chandra Belani<sup>3</sup>, Francisco Robert<sup>4</sup>,  
Evanthia Galanis<sup>5</sup>, Victoria M Richon<sup>6</sup>, José Garcia-Vargas<sup>6</sup>, Cesar Sanz-  
Rodriguez<sup>7</sup> and Syed Rizvi<sup>6</sup>

Address: <sup>1</sup>Hackensack University Medical Center, Hackensack, NJ, USA, <sup>2</sup>H. Lee Moffitt Cancer Center, Tampa, FL, USA, <sup>3</sup>Penn State Cancer Institute, Hershey, PA, USA, <sup>4</sup>University of Alabama, Birmingham, AL, USA, <sup>5</sup>Mayo Clinic College of Medicine, Rochester, MN, USA, <sup>6</sup>Merck Research Laboratories, Upper Gwynedd, PA, USA and <sup>7</sup>Merck Research Laboratories, Madrid, Spain

Email: David Siegel\* - dsiegel@hmed.com; Mohamad Hussein - mhusein@celgene.com; Chandra Belani - cbelani@hmc.psu.edu; Francisco Robert - pacorobertuab@cs.com; Evanthia Galanis - galanis.evanthia@mayo.edu; Victoria M Richon - vrchon@epizymebio.com; José Garcia-Vargas - jose\_garcia-vargas@merck.com; Cesar Sanz-Rodriguez - cesar\_sanzrodriguez@merck.com; Syed Rizvi - syed\_rizvi@merck.com

\* Corresponding author

Published: 27 July 2009

Received: 29 May 2009

*Journal of Hematology & Oncology* 2009, **2**:31 doi:10.1186/1756-8722-2-31

Accepted: 27 July 2009

This article is available from: <http://www.jhonline.org/content/2/1/31>

© 2009 Siegel et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

Vorinostat (Zolinza<sup>®</sup>), a histone deacetylase inhibitor, was approved by the US Food and Drug Administration in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. This review summarizes evidence on the use of vorinostat in solid and hematologic malignancies and collated tolerability data from the vorinostat clinical trial program. Pooled vorinostat clinical trial data from 498 patients with solid or hematologic malignancies show that vorinostat was well tolerated as monotherapy or combination therapy. The most commonly reported drug-related adverse events (AEs) associated with monotherapy ( $n = 341$ ) were fatigue (61.9%), nausea (55.7%), diarrhea (49.3%), anorexia (48.1%), and vomiting (32.8%), and Grade 3/4 drug-related AEs included fatigue (12.0%), thrombocytopenia (10.6%), dehydration (7.3%), and decreased platelet count (5.3%). The most common drug-related AEs observed with vorinostat in combination therapy ( $n = 157$ , most of whom received vorinostat 400 mg qd for 14 days) were nausea (48.4%), diarrhea (40.8%), fatigue (34.4%), vomiting (31.2%), and anorexia (20.4%), with the majority of AEs being Grade 2 or less. In Phase I trials, combinations with vorinostat were generally well tolerated and preliminary evidence of anticancer activity as monotherapy or in combination with other systemic therapies has been observed across a range of malignancies. Ongoing and planned studies will further evaluate the potential of vorinostat in combination therapy, including combinations with radiation, in patients with diverse malignancy types, including non-small-cell lung cancer, glioblastoma multiforme, multiple myeloma, and myelodysplastic syndrome.

### Histone Deacetylase Inhibition with Vorinostat as a Target in Oncology

Advanced or refractory malignancy remains an area of high unmet medical need as patients often relapse and


curative therapy is elusive. The mainstay of treatment is generally cytotoxic chemotherapy which can have limited efficacy and is often associated with significant toxicity; there is a need for novel agents that are not only effective

but also well tolerated. In particular, there has been increasing interest in targeted therapies which work at an epigenetic level to influence gene expression and ultimately control tumor growth and proliferation. Histone deacetylase (HDAC) inhibitors represent one such class of new mechanism-based anticancer drugs [1].

Modifications to histones influence chromatin structure, and ultimately gene transcription, including those coding for tumor suppressor proteins. One of the key histone modifications that controls gene transcription is acetylation, which is regulated by two opposing enzymatic activities (histone acetyltransferases [HATs] and HDACs) [1]. Histone acetylation leads to an open chromatin structure, and allows access to transcription binding sites. Although histones are one of the targets of HATs and HDACs, many nonhistone proteins, including transcription factors, tubulin and heat shock protein 90, can also be regulated by acetylation [2,3].

HDACs have been shown to be overexpressed in human cancers, such as gastric, prostate and colon cancer, and are involved in the regulation of transcription with recruitment by oncogenic transcription factors [4]. Therefore, the inhibition of HDACs is a rational target for the development of novel anticancer therapy. To date, 18 HDACs have been identified in mammalian cells, which are categorized into different classes, based on their homology to yeast deacetylases [5]. By inhibiting these enzymes, HDAC inhibitors permit chromatin to assume a more relaxed conformational state, thereby allowing transcription of genes involved in tumor suppression, cell-cycle arrest, cell differentiation, and apoptosis (Figure 1[4]) [6].

A variety of HDAC inhibitors are in clinical development and are being assessed in a number of different cancer indications [7]. There are several chemical families among the HDAC inhibitors, including short-chain fatty acids (butyrate, valproic acid), hydroxamates (vorinostat, tri-



<sup>a</sup>The sites of action of other antitumor agents are also shown

**Figure 1**  
**Proposed mechanism of action of vorinostat in inducing tumor cell-cycle arrest and apoptosis<sup>a</sup> [4].** HDAC, histone deacetylase; TS, thymidylate synthase; VEGF, vascular endothelial growth factor; 17-AAG, 17-allylamino-17-demethoxygeldanamycin; 5-FU, 5-fluorouracil. Reprinted by permission from Macmillan Publishers Ltd: Richon VM. Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. *Br J Cancer* 2006; 95 (Suppl 1): S2–S6, copyright 2006.

chostatin A, LBH-589, PXD-101), cyclic tetrapeptides (depsipeptide), and benzamides (MS-275, MGCD-0103). Vorinostat (Zolinza®; Merck & Co., Inc., Whitehouse Station, NJ, USA) was the first HDAC inhibitor licensed for clinical use and has been shown to inhibit the activity of class I and II HDACs, in particular HDAC1, HDAC2, HDAC3 (class I), and HDAC 6 (class II) at low nanomolar concentrations [4,5,8]. In addition to chromatin histone proteins that are involved in the regulation of gene expression, HDACs have many nonhistone protein targets including transcription factors and proteins that regulate cell proliferation, migration, and death [5]. For example, HDAC 6, which is predominantly cytosolic, has been shown to have roles in microtubule stability and function via the acetylation of  $\alpha$ -tubulin [9], in the regulation of heat-shock protein 90 [10], and in the formation of aggregates of ubiquitinated proteins [11].

### **Vorinostat Monotherapy for Solid and Hematologic Malignancies**

Vorinostat is the first HDAC inhibitor approved for the treatment of cancer: in October 2006, the US Food and Drug Administration granted approval to vorinostat for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent or recurrent disease on or following two systemic therapies [12]. This approval was based on a pivotal Phase IIb multicenter trial of vorinostat monotherapy, which included 74 patients with persistent, progressive or recurrent, stage IB or higher CTCL who had received at least two prior systemic therapies including bexarotene [13]. The objective response rate was 30% and the most common drug-related adverse events (AEs) were diarrhea (49%), fatigue (46%), nausea (43%), and anorexia (26%). Most of these AEs were Grade 2 or lower but 21/74 patients (28%) had drug-related Grade 3/4 AEs, the most common being fatigue (5%), pulmonary embolism (5%), thrombocytopenia (5%), and nausea (4%). Similar results were observed in a second, smaller Phase II study including 33 patients with CTCL who were refractory to or intolerant of conventional therapy [14]. In this study, 8/33 patients (24%) achieved a partial response and the most common drug-related AEs were fatigue (73%), thrombocytopenia (54%), diarrhea (49%), nausea (49%), dysgeusia (46%), dry mouth (35%), and weight loss (27%). The most common drug-related Grade 3 or 4 AEs were thrombocytopenia (19%) and dehydration (8%). Overall, these studies showed that vorinostat as monotherapy was effective in advanced CTCL and had an acceptable safety profile. Vorinostat is included in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology™ for non-Hodgkin's lymphoma (NHL), where it is listed as a systemic therapy option for patients with mycosis fungoides/Sézary syndrome who have failed multiple treat-

ments with local and skin-directed therapy or who have unfavorable prognostic features [15].

Phase I studies have indicated that vorinostat monotherapy has an acceptable safety profile in patients with a variety of solid and hematologic malignancies [16-25]. Similarly, Phase II studies in patients with head and neck cancer [26], diffuse large B-cell lymphoma (DLBCL) [27], glioblastoma multiforme (GBM) [28], hormone-refractory prostate cancer [29], breast cancer [30], NHL [31], Hodgkin's lymphoma [32], non-small-cell lung cancer (NSCLC) [33], breast, colorectal or NSCLC [34], epithelial ovarian or primary peritoneal carcinoma [35], and myelodysplastic syndrome [36], have also shown that vorinostat is well tolerated, with preliminary activity as monotherapy against NHL and GBM [28,31].

In the Phase II study of vorinostat monotherapy in patients with GBM, 66 patients who had received  $\leq 1$  prior chemotherapy regimen for progressive/recurrent GBM, and who were not undergoing surgery, were treated with 200 mg vorinostat bid on Days 1-14 every 3 weeks [28]. The primary efficacy endpoint was met; nine of the first 52 patients were progression-free at 6 months, and the median overall survival was 5.7 months. As in the earlier CTCL studies, the majority of AEs were Grade 2 or lower; the most common Grade 3 or 4 AEs were thrombocytopenia (22%), fatigue (17%), neutropenia (8%), dehydration (6%), and hypernatremia (5%). In a subgroup of five patients with surgical recurrent GBM who received vorinostat prior to surgery, immunohistochemical analysis of paired baseline and post-vorinostat samples showed increased acetylation levels of histones H2B and H4, and histone H3 following vorinostat therapy in four of five and three of five patients, respectively. Microarray analysis of RNA extracted from the same paired samples revealed changes in the expression pattern of genes regulated by vorinostat, such as upregulation of E-cadherin ( $p = 0.02$ ). These results suggest that the dose and schedule of vorinostat employed in this Phase II trial had a biologic effect on glioblastoma tumors, affecting target pathways in GBM. The authors of this study concluded that vorinostat has single-agent activity in GBM and is well tolerated.

In the other Phase II monotherapy study that demonstrated preliminary clinical activity, of 37 enrolled patients with relapsed or refractory follicular, marginal zone or mantle cell lymphoma, five patients achieved a complete response and five a partial response [31].

While there has not been clear evidence of QTc prolongation due to vorinostat in either preclinical or clinical studies to date, isolated clinical events of QTc prolongation in previous vorinostat studies have been observed, and QTc

prolongation has been reported for other HDAC inhibitors [37,38]. However, in a Phase I randomized, placebo-controlled, crossover study conducted in 25 patients with relapsed or refractory advanced cancer, administration of a single suprathreshold dose of vorinostat (800 mg) did not prolong the QTcF interval (monitored over 24 hours) [39]. The upper limit of the 90% confidence interval for the placebo-adjusted mean change-from-baseline of vorinostat was less than 10 ms at every time point for all 24 patients included in the QTcF analysis. For the vorinostat and placebo groups, there were no observed QTcF changes from baseline values >30 ms and only one patient experienced a QTcF interval >450 ms (seen following both vorinostat and placebo administration).

The acceptable safety profile of vorinostat observed in these studies, together with the monotherapy activity in some tumor types, provide a good foundation for the use of vorinostat in combination regimens.

### **Biologic Rationale for Vorinostat Use in Combination with Other Therapies**

Combination chemotherapy or chemoradiotherapy are frequently employed in preference to single-agent therapy to maximize treatment efficacy, but can be associated with increased toxicity. Vorinostat has a different mechanism of action compared with many other antineoplastic agents; therefore, it may be able to improve clinical efficacy in combination with other systemic agents where there are no or minimal overlapping toxicities. In addition, it has been hypothesized that the mechanism of action of HDAC inhibitors, through the acetylation of key lysine residues in core histones leading to a more relaxed chromatin configuration, may allow enhanced access to the DNA by another antineoplastic agent that directly interacts with DNA (e.g. cisplatin) resulting in synergistic activity [40].

Combination strategies may also help to overcome potential mechanisms of drug resistance to HDAC inhibitors [41]. These include other chromatin alterations such as DNA methylation, which together with hypoacetylation is thought to cooperate to induce gene silencing. Thus, the combination of HDAC inhibitors with hypomethylating agents, such as azacitidine and decitabine, is rational. Any protection against the cellular oxidative stress induced by HDAC inhibitors, such as proteins that participate in the stress response to oxidative damage, has also been postulated as a mechanism of resistance to HDAC inhibitors. In this case, the combination of HDAC inhibitors with other agents that also induce oxidative damage, such as bortezomib or doxorubicin, could help to overwhelm the stress response.

Numerous preclinical studies of vorinostat in combination with other cancer therapies have demonstrated syner-

gistic or additive activity in cell lines from a wide range of solid and hematologic malignancies [4,5], including NSCLC [42-46], multiple myeloma (MM) [47-49], and leukemia [45,50-61]). In various models, treatment with vorinostat in combination resulted in synergistic apoptotic effects with associated increases in reactive oxygen species and mitochondrial injury, caspase and poly (ADP-ribose) polymerase activation. Synergistic activity has also been demonstrated *in vivo*; in one study in orthotopic human pancreatic tumors, the addition of vorinostat to bortezomib, and the resulting inhibition of HDAC 6 and disruption of aggresome formation, led to much higher levels of apoptosis and significantly reduced pancreatic tumor weight compared with either agent alone [62].

Some preclinical data also indicate that the activity of vorinostat in combination with radiation may be promising [63-66]. Vorinostat is to be tested in the adjuvant setting of GBM in combination with radiotherapy and temozolomide [67], and further trials are ongoing or planned in brain metastases and other indications where radiotherapy is used alone and in combination.

On the basis of these and other studies, vorinostat in combination is being evaluated in clinical trials in patients with a variety of solid and hematologic malignancies.

### **Vorinostat in Combination for Advanced Solid Tumors**

A number of Phase I studies have been undertaken to determine the recommended Phase II dose of vorinostat in combination with other established chemotherapy agents in patients with advanced or refractory solid tumors [68-74] (Table 1[68-74]). In one of these studies, in which vorinostat was combined with carboplatin and paclitaxel, particularly promising activity was noted in patients with advanced NSCLC, with 10/19 patients (53%; 18 chemo-naïve) experiencing a partial response and 4/19 (21%) stable disease [68]. In comparison, treatment with carboplatin-paclitaxel of chemo-naïve patients with advanced NSCLC results in response rates of approximately 15–25% [75-77]. The combination was generally well tolerated. Grade 3/4 toxicity was predominantly hematologic: of 28 treated patients, 2 patients experienced Grade 4 febrile neutropenia, and 8 and 14 patients experienced Grade 3 and 4 neutropenia, respectively; although this was more than expected from carboplatin-paclitaxel alone, with rates of Grade 4 neutropenia of 17–43% previously reported [75-77], there was no definite relationship found between the dose and schedule of vorinostat and the incidence of Grade 3/4 neutropenia. Dose-limiting toxicities (DLTs) were Grade 3 vomiting (one patient) and Grade 4 febrile neutropenia (one patient) and the recommended Phase II dose for vorinostat in combination with carboplatin-paclitaxel was 400 mg qd for 14 days every 3 weeks. In another study, vorinostat was

**Table 1: Phase I Results of Vorinostat in Combination Therapy in Patients with Advanced Solid Tumors**

Tumor Type	No. Pts	Treatment	Summary of Results	Ref
Advanced solid	22	Vorinostat + pemetrexed + cisplatin	DLTs: fatigue (2), dehydration (2), neutropenia (1), cerebral ischemia (1) DVT (1) 19 patients evaluable for response: 1 CR, 1 PR, 11 SD, 6 PD Vorinostat 300 mg qd for 7/21 days was tolerable with cisplatin 75 mg/m <sup>2</sup> + pemetrexed 500 mg/m <sup>2</sup>	[70]
Advanced solid	20	Vorinostat + doxorubicin	DLTs: thrombocytopenia (1), fatigue (1), nausea/vomiting, and anorexia (1) Response: 1 PR, 3 SD, 11 PD, 5 NE Tolerated dose of vorinostat higher than approved single-agent dose in patients with hematologic malignancies	[71]
Advanced colorectal	21	Vorinostat + 5-FU/LV + oxaliplatin	DLTs: fatigue (1), fatigue and diarrhea (1), fatigue, anorexia, and dehydration (1) Response: 11 SD (5 confirmed) of 21 evaluable patients Recommended dose: vorinostat 300 mg bid on Days 1–7 + 5-FU/LV + oxaliplatin on Day 4 every 14 days	[74]
Advanced solid	28	Vorinostat + carboplatin + paclitaxel	DLTs: vomiting (1), febrile neutropenia (1) Response: 11 PR, 7 SD in 25 evaluable patients (of 19 pts with NSCLC [18 chemo-naïve], 10 [53%] had a PR) Phase II regimen: vorinostat 400 mg qd on Days 1–14 + carboplatin AUC 6 mg/mL × min + paclitaxel 200 mg/m <sup>2</sup>	[68]
Refractory solid	22	Vorinostat + bortezomib	DLTs: fatigue (3), hyponatremia (1), elevated ALT (1) MTD (step A): vorinostat 400 mg qd on Days 1–14 + bortezomib 1.3 mg/m <sup>2</sup> on Days 1, 4, 8, and 11 of a 21-day cycle Clinical activity observed: 1 PR >9 months in a patient with refractory soft tissue sarcoma	[72]
Advanced solid	26	Vorinostat + capecitabine	DLTs: diarrhea (1), fatigue (2), nausea/vomiting (1) Response: 4 PR (3 confirmed), 18 SD, 4 PD Recommended Phase II regimen: vorinostat 300 mg qd + capecitabine 1000 mg/m <sup>2</sup> bid	[73]
Malignant glioma	19	Vorinostat + temozolomide	DLTs: thrombocytopenia (2), fatigue (3), nausea (1) MTD: vorinostat 300 mg qd on Days 1–14 + temozolomide 150 mg/m <sup>2</sup> /day on Days 1–5 every 28 days	[69]

DLT, dose-limiting toxicity; ALT, alanine aminotransferase; MTD, maximum tolerated dose; PR, partial response; DVT, deep vein thrombosis; CR, complete response; PD, disease progression; NE, not evaluable; NSCLC, non-small-cell lung cancer; AUC, area under the curve; 5-FU/LV, 5-fluorouracil/leucovorin.

combined with doxorubicin without exacerbation of doxorubicin toxicity, with a tolerated vorinostat dose of 400 mg bid dosed on Days 1–3 every week [71].

The results of disease-specific Phase I vorinostat combination studies in patients with malignant gliomas [69] or colorectal cancer [74] have also been published (Table 1[68-74]). In patients with malignant gliomas treated with escalating doses of vorinostat plus temozolomide, DLTs were Grade 3 thrombocytopenia, Grade 3 nausea, and Grade 4 thrombocytopenia each reported in one patient, and Grade 3 fatigue reported in three patients [69]. The recommended Phase II dose for vorinostat in combination with temozolomide was 300 mg qd on Days 1–14 every 28 days.

Overall, the data of vorinostat in combination regimens for the treatment of a variety of advanced solid tumors demonstrate that, when used with other chemotherapy agents, vorinostat can be well tolerated and the prelimi-

nary anticancer activity noted supports the conduct of disease-specific Phase II studies. A range of ongoing studies will further evaluate the role of vorinostat in combination therapy in a variety of advanced solid tumors; these include Phase I/II studies with vorinostat in combination in patients with advanced breast cancer, small-cell lung cancer, and NSCLC, and Phase II studies in combination with tamoxifen or carboplatin and paclitaxel in patients with advanced breast cancer or in combination with carboplatin and paclitaxel in patients with advanced NSCLC [67].

**Vorinostat in Combination for Hematologic Malignancies**

Vorinostat also has potential in combination with chemotherapy or other biologic agents as treatment for hematologic malignancies. The combination of vorinostat plus the proteasome inhibitor bortezomib has been investigated in two Phase I studies in heavily pretreated patients with advanced relapsed or refractory MM [78,79] (Table

**Table 2: Phase I Results of Vorinostat in Combination Therapy in Patients With Hematologic Malignancies<sup>a</sup>**

Tumor Type	No. Pts	Treatment	Summary of Results	Ref
Relapsed multiple myeloma	23	Vorinostat + bortezomib	DLTs: prolonged QT interval (1), fatigue (1) MTD vorinostat 400 mg qd on Days 4–11 + bortezomib 1.3 mg/m <sup>2</sup> on Days 1, 4, 8, and 11 every 21 days Response: 2 VGPR, 7 PR, 10 SD (21 evaluable patients)	[78]
Relapsed, refractory or poor prognosis acute leukemia or refractory anemia with excess blasts-2	22	Vorinostat + flavopiridol (bolus or 'hybrid' infusion schedules)	DLTs: infectious colitis with sepsis (1 [bolus]) and atrial fibrillation (1 ['hybrid']) MTD: not yet reached on vorinostat 200 mg tid given in a 'hybrid' schedule with flavopiridol at 30/30 mg/m <sup>2</sup> (load/infusion) on Days 1 and 8 of a 21-day cycle, identification of the MTD and recommended phase II dose is ongoing Response: 10 patients experienced some clinical benefit (20 evaluable patients)	[81]
Advanced acute leukemia	20	Vorinostat + idarubicin	DLTs: myelosuppression, encephalopathy, and dysphagia 2 CR and 2 complete marrow responses observed in patients who had failed previous anthracycline-based therapy Recruitment ongoing at vorinostat 400 mg tid for 3 days + idarubicin 12 mg/m <sup>2</sup> for 3 days every 14 days	[82]
Relapsed or newly-diagnosed acute myelogenous leukemia or myelodysplastic syndrome	70	Vorinostat + decitabine (concurrent or sequential regimens)	DLT: prolonged QT interval (1 [sequential]) Response: concurrent (n = 34), 7 CR, 2 PR, 2 HI, 12 SD; sequential (n = 36), 3 CR, 2 HI, 16 SD MTD not reached Last cohort: vorinostat 400 mg qd for 14 days (Days 1–14 concurrent or Days 6–19 sequential) + decitabine 20 mg/m <sup>2</sup> /day on Days 1–5 every 28 days	[83]
Relapsed, refractory or poor prognosis leukemia	31	Vorinostat + decitabine	DLTs: pulmonary embolism and diarrhea (1) Response: 1 CR, 4 significant reduction in bone marrow blasts, 4 SD, 14 PD, 7 NE (30 evaluable patients) Last cohort: decitabine 25 mg/m <sup>2</sup> daily for 5 days followed by vorinostat 200 mg tid for 14 days	[84]
Relapsed or refractory multiple myeloma	18	Vorinostat + lenalidomide + dexamethasone	DLTs: none yet reported MTD: not yet reached, DLT evaluation ongoing in patients enrolled to vorinostat 400 mg qd for 14 days (Days 1–7 and 15–21), combined with lenalidomide 25 mg qd for 21 days, and dexamethasone 40 mg/day (Days 1, 8, 15, and 22) every 28 days Response: 1 CR, 4 PR, 1 MR, 5 SD (15 evaluable patients)	[87]
Myelodysplastic syndrome and acute myeloid leukemia	28	Vorinostat + azacitidine	DLTs: not reported Response: 9 CR, 2 incomplete CR, 7 HI, 2 SD (21 evaluable patients) Last cohort: azacitidine 55 mg/m <sup>2</sup> /day on Days 1–7 + vorinostat 300 mg bid on Days 3–5 every 28 days	[85]
Advanced multiple myeloma	34	Vorinostat + bortezomib	DLTs: transient AST elevation (1), thrombocytopenia (1) MTD not yet reached, the maximum administered dose was vorinostat 400 mg qd on Days 1–14 + bortezomib 1.3 mg/m <sup>2</sup> on Days 1, 4, 8, and 11 every 21 days. Response: 12 PR, 6 MR, 13 SD (33 evaluable patients). In 17 evaluable patients who had received prior bortezomib therapy, 6 PR, 4 MR, 7 SD	[79]
Acute myeloid leukemia	27	Vorinostat + decitabine	DLT: fatigue (1) Response: 1 incomplete CR, 1 morphologic leukemia-free (without neutrophil recovery), 3 PR (25 evaluable patients) MTD not reached: maximum dose vorinostat 200 mg bid on Days 1–21 + decitabine 20 mg/m <sup>2</sup> /day on Days 1–5 every 28 days	[86]

<sup>a</sup>Only trials including at least 15 patients are reported in this table.

DLT, dose-limiting toxicity; AST, aspartate aminotransferase; MTD, maximum tolerated dose; PR, partial response; MR, minimal response; SD, stable disease; VGPR, very good partial response; nCR, near complete response; PD, progressive disease; CR, complete response; NE, not evaluable; HI, hematologic improvement.

2[78-87]). In one of these studies, one patient receiving vorinostat 400 mg qd on Days 1–14 plus bortezomib 0.9 mg/m<sup>2</sup> on Days 1, 4, 8, and 11 every 21 days experienced a DLT of Grade 3 transient aspartate aminotransferase elevation and one patient receiving vorinostat 400 mg qd plus bortezomib 1.3 mg/m<sup>2</sup> experienced a DLT of Grade 4 thrombocytopenia [79]. The most common ( $\geq 10\%$  of patients) Grade 3/4 drug-related AEs were thrombocytopenia (38%) and fatigue (12%). Dose escalation was successfully completed and the maximum tolerated dose (MTD) was not reached. The maximum administered dose was vorinostat 400 mg qd on Days 1–14 plus bortezomib 1.3 mg/m<sup>2</sup> on Days 1, 4, 8, and 11 every 21 days. In the second of these studies, MTD was established at 400 mg qd on Days 4–11 plus bortezomib 1.3 mg/m<sup>2</sup> on Days 1, 4, 8, and 11 every 21 days, with DLTs of Grade 3 prolonged QT interval and Grade 3 fatigue each reported in one patient [78].

Efficacy appeared to be similar in these two studies: in the first study, of 33 patients evaluable for efficacy, 12 had a partial response, 6 had a minimal response (overall 55% response), and 13 had stable disease; 2 patients experienced progressive disease [79]. In the second study, which included more heavily pretreated patients (median number of prior regimens 7 versus 3), 9/21 patients (43%) had a response, 10 had stable disease, and 2 had disease progression [78]. In contrast, only modest single-agent activity was observed with vorinostat in patients with relapsed/refractory MM, with 1/10 evaluable patients having a minimal response and 9/10 stable disease [25].

Preliminary data from Phase I studies have shown that vorinostat is well tolerated when combined with cytarabine and etoposide for the treatment of advanced acute leukemia and high-risk myelodysplastic syndrome [80], with flavopiridol in refractory or high-risk acute myeloid leukemia [81], or in combination with lenalidomide and dexamethasone in patients with relapsed or refractory MM [87]. Other ongoing Phase I studies of vorinostat combinations in patients with hematologic malignancies have also shown that combinations with idarubicin, decitabine or azacitidine are well tolerated [82-86] and have suggested potential anticancer activity of vorinostat in combination with idarubicin, in patients with advanced leukemia [82], decitabine, in patients with advanced leukemia [84], acute myeloid leukemia [83,86], or myelodysplastic syndrome [83], or azacitidine in patients with myelodysplastic syndrome or acute myeloid leukemia [85] (Table 2[78-87]). Again, the tolerability profile and preliminary anticancer activity support the continuing investigation of combinations of vorinostat with other chemotherapy agents in disease-specific Phase II studies. Ongoing clinical trials will further evaluate the role of vorinostat in combination therapy in hematologic

malignancies, such as MM, leukemia, and lymphoma [67].

### Safety and Tolerability of Vorinostat – Overall Experience from the Vorinostat Clinical Trial Program

Analysis of combined safety data from the vorinostat clinical trial program of Phase I and II trials demonstrate that vorinostat has an acceptable safety and tolerability profile either as monotherapy or combination therapy in patients with a variety of solid and hematologic malignancies. At a cut-off date of April 2008, collated data were available for 341 patients who received vorinostat as monotherapy for either solid tumors (mesothelioma, head and neck, renal, thyroid, laryngeal, breast, colorectal, NSCLC, and gastric cancers) or for hematologic malignancies (acute myeloid leukemia, chronic lymphocytic leukemia, or chronic myeloid leukemia, NHL [including CTCL, peripheral T-cell lymphoma, DLBCL, and follicular lymphoma], Hodgkin's disease, myelodysplastic syndrome or MM). Of these patients, 156 patients were treated at a dose of 400 mg qd (the current FDA-approved dose for patients with CTCL). The most commonly reported drug-related AEs were fatigue (62%), nausea (56%), diarrhea (49%), anorexia (48%), and vomiting (33%) (Table 3). Grade 3/4 drug-related AEs included fatigue (12%), thrombocytopenia (11%), dehydration (7%), and decreased platelet count (5%). Three drug-related deaths (ischemic stroke, tumor hemorrhage, unspecified) were observed.

Similarly, collated safety data from 157 patients who received vorinostat (most commonly at 400 mg qd for 14 days) in combination with other systemic therapies in the vorinostat clinical trial program were available for analysis (cut-off date of April 2008). Patients received vorinos-

**Table 3: Drug-Related Adverse Events Occurring in  $\geq 15\%$  of Patients Who Received Vorinostat Monotherapy in the Vorinostat Clinical Trial Program (Data Cut-Off April 2008)**

Adverse Event	No. (%) of Patients (N = 341)	
	All Grades	Grade 3 or 4
Fatigue	211 (61.9)	41 (12.0)
Nausea	190 (55.7)	14 (4.1)
Diarrhea	168 (49.3)	14 (4.1)
Anorexia	164 (48.1)	17 (5.0)
Vomiting	112 (32.8)	5 (1.5)
Blood creatinine increased	88 (25.8)	2 (0.6)
Weight decreased	86 (25.2)	4 (1.2)
Hyperglycemia	79 (23.2)	10 (2.9)
Thrombocytopenia	71 (20.8)	36 (10.6)
Platelet count decreased	65 (19.1)	18 (5.3)
Hemoglobin decreased	60 (17.6)	10 (2.9)
Constipation	60 (17.6)	3 (0.9)
Dysgeusia	59 (17.3)	0 (0.0)

tat in combination with other systemic therapies for the treatment of advanced cancer, MM, CTCL, and NSCLC. In combination, the most commonly reported drug-related AEs were nausea (48%), diarrhea (41%), fatigue (34%), vomiting (31%), and anorexia (20%) (Table 4). The most common Grade 3/4 events were fatigue (13%), thrombocytopenia (10%), neutropenia (8%), diarrhea (6%), and nausea (5%). There was one drug-related AE leading to death due to hemoptysis in one patient with NSCLC.

Overall, vorinostat was well tolerated, with the majority of AEs being Grade 2 or less, and vorinostat was not associated with the levels of hematologic toxicity commonly found with other antineoplastic agents. Furthermore, dose modifications were usually not required in the majority of patients who received vorinostat as monotherapy or in combination therapy.

**Conclusion**

Vorinostat is generally well tolerated and has shown potential anticancer activity against a variety of hematologic and solid tumors, particularly in combination therapy, as well as in monotherapy. As monotherapy, combined data from the vorinostat clinical trial program demonstrate that vorinostat has an acceptable safety and tolerability profile, with the most common Grade 3/4 AEs being fatigue (12%) and thrombocytopenia (11%). Although the tolerability data from Phase I trials of vorinostat in combination are limited, the individual trial data suggest that the combinations are also generally well tolerated, and this appears to be substantiated by pooled safety data from the vorinostat clinical trial program. Despite concerns, the available data suggest that there do not appear to be any unexpected toxicities when vorinostat is combined with other antineoplastic agents. These preliminary clinical results from Phase I and II trials support the rationale for combining vorinostat with other chemotherapy agents and/or radiotherapy as a means of increasing the therapeutic index of cancer therapy.

**Table 4: Drug-Related Adverse Events Reported by ≥ 15% of Patients Who Received Vorinostat Combination Therapy in the Vorinostat Clinical Trial Program (Data Cut-Off April 2008)**

Adverse Event	No. (%) of Patients (N = 157)	
	All Grades	Grade 3 or 4
Nausea	76 (48.4)	8 (5.1)
Diarrhea	64 (40.8)	9 (5.7)
Fatigue	54 (34.4)	21 (13.4)
Vomiting	49 (31.2)	6 (3.8)
Anorexia	32 (20.4)	4 (2.5)
Dehydration	28 (17.8)	6 (3.8)
Thrombocytopenia	25 (15.9)	15 (9.6)
Anemia	25 (15.9)	4 (2.5)

**Competing interests**

SR, JGV, and CSR are employees of Merck & Co., Inc. VMR was a founder of Aton Pharma Inc. and an employee of Merck & Co., Inc., and is now employed by EpiZyme Inc. MH is now employed by the Celgene Corporation.

Merck employees may own shares or stock options of Merck & Co., Inc. CB is a consultant for Merck & Co., Inc. DS, EG, and FR have no relevant financial disclosures to declare.

**Authors' contributions**

All authors (DS, MH, CB, FR, EG, VMR, SR, JGV and CSR) participated in drafting and editing the manuscript and all authors read and approved the final manuscript.

**Acknowledgements**

We thank Dr Annette Smith, from Complete Medical Communications, who provided medical writing support funded by Merck.

**References**

1. Pan LN, Lu J, Huang B: **HDAC inhibitors: a potential new category of anti-tumor agents.** *Cell Mol Immunol* 2007, **4**:337-343.
2. Bolden JE, Peart MJ, Johnstone RW: **Anticancer activities of histone deacetylase inhibitors.** *Nat Rev Drug Discov* 2006, **5**:769-784.
3. Minucci S, Pelicci PG: **Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.** *Nat Rev Cancer* 2006, **6**:38-51.
4. Richon VM: **Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor.** *Br J Cancer* 2006, **95**(Suppl 1):S2-S6.
5. Marks PA: **Discovery and development of SAHA as an anti-cancer agent.** *Oncogene* 2007, **26**:1351-1356.
6. Marks PA, Richon VM, Rifkind RA: **Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells.** *J Natl Cancer Inst* 2000, **92**:1210-1216.
7. Cang S, Ma Y, Liu D: **New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.** *J Hematol Oncol* 2009, **2**:22.
8. Johnstone RW: **Suberanilohydroxamic acid.** *Aton Pharma. IDrugs* 2004, **7**:674-682.
9. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL: **Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation.** *Proc Natl Acad Sci USA* 2003, **100**:4389-4394.
10. Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, et al.: **HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor.** *Mol Cell* 2005, **18**:601-607.
11. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP: **The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress.** *Cell* 2003, **115**:727-738.
12. Mann BS, Johnson JR, Sridhara R, Abraham E, Booth b, Verbois L, et al.: **Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma.** *Clin Cancer Res* 2007, **13**:2318-2322.
13. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, et al.: **Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.** *J Clin Oncol* 2007, **25**:3109-3115.
14. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, et al.: **Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).** *Blood* 2007, **109**:31-39.
15. NCCN: **NCCN Clinical Practice Guidelines in Oncology™: Non-Hodgkin's lymphomas V.3.2008.** [<http://www.nccn.org>].



16. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, et al.: **Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.** *J Clin Oncol* 2005, **23**:3923-3931.
17. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, et al.: **Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.** *Clin Cancer Res* 2003, **9**:3578-3588.
18. O'Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, Gregor-Cortelli B, et al.: **Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.** *J Clin Oncol* 2006, **24**:166-173.
19. Krug LM, Curley T, Schwartz L, Richardson S, Marks P, Chiao J, et al.: **Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid.** *Clin Lung Cancer* 2006, **7**:257-261.
20. Rubin EH, Agrawal NGB, Friedman EJ, Scott P, Mazina KE, Sun L, et al.: **A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat administered orally to patients with advanced cancer.** *Clin Cancer Res* 2006, **12**:7039-7045.
21. Tobinai K, Watanabe T, Kobayashi Y, Yamasaki S, Morita-Hoski Y, Yokoyama H, et al.: **Phase I study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients (pts) with non-Hodgkin lymphoma (NHL) in Japan [abstract].** *J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part 1* 2007, **25**:18521.
22. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, et al.: **Phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced leukemias and myelodysplastic syndromes.** *Blood* 2008, **111**:1060-1066.
23. Fouladi M, Park J, Sun J, Fraga C, Ames MM, Stewart CF, et al.: **A phase I trial of vorinostat in children with refractory solid tumors: A Children's Oncology Group Study. [abstract].** *J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part 1* 2007, **25**:9569.
24. Fujiwara Y, Yamamoto N, Yamada K, Yamada Y, Shimoyama T, Koizumi F, et al.: **A phase I and pharmacokinetic/pharmacodynamic study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in Japanese patients with solid tumor [abstract].** *J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part 1* 2007, **25**:14015.
25. Richardson P, Mitsiades C, Colson K, Reilly E, McBride L, Chiao J, et al.: **Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma.** *Leuk Lymphoma* 2008, **49**:502-507.
26. Blumenschein GR Jr, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, et al.: **Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.** *Invest New Drugs* 2008, **26**:81-87.
27. Crump M, Coiffier B, Jacobsen ED, Sun L, Ricker JL, Xie H, et al.: **Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.** *Ann Oncol* 2008, **19**:964-969.
28. Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, et al.: **Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.** *J Clin Oncol* 2009, **27**:2052-2058.
29. Hussain M, Dunn R, Rathkopf D, Stadler W, Wilding G, Smith DC, et al.: **Suberoylanilide hydroxamic acid (vorinostat) post chemotherapy in hormone refractory prostate cancer (HRPC) patients (pts): A phase II trial by the Prostate Cancer Clinical Trials Consortium (NCI 6862) [abstract].** *J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part 1* 2007, **25**:5132.
30. Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, Portnow J, et al.: **A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California cancer consortium study.** *Clin Cancer Res* 2008, **14**:7138-7142.
31. Kirschbaum MH, Popplewell L, Nademanee A, Pullarkat V, Delioukina M, Zain J, et al.: **A phase 2 study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed or refractory indolent non-hodgkin's lymphoma. A California Cancer Consortium study. [abstract].** *Haematologica* 2009, **94**(Suppl 2):0409.
32. Kirschbaum MH, Goldman BH, Zain JM, Cook JR, Rimsza LM, Forman SJ, et al.: **Vorinostat (suberoylanilide hydroxamic acid) in relapsed or refractory Hodgkin lymphoma: SWOG 0517 [abstract].** *Blood (ASH Annual Meeting Abstracts)* 2007, **110**:2574.
33. Traynor AM, Dubey S, Eickhoff JC, Kolesar JM, Schell K, Huie MS, et al.: **Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study.** *J Thorac Oncol* 2009, **4**:522-526.
34. Vansteenkiste J, Cutsem EV, Dumez H, Chen C, Ricker JL, Randolph SS, et al.: **Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer.** *Invest New Drugs* 2008, **26**:483-488.
35. Modesitt SC, Sill M, Hoffman JS, Bender DP: **A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.** *Gynecol Oncol* 2008, **109**:182-186.
36. Garcia-Manero G, Silverman LB, Gojo I, Michaelis L, Parmar S, Goldberg SL, et al.: **A randomized phase IIa study of vorinostat in patients with low or intermediate-1 risk myelodysplastic syndromes: preliminary results [abstract].** *Blood (ASH Annual Meeting Abstracts)* 2008, **112**:5084.
37. Stadler WM, Margolin K, Ferber S, McCulloch W, Thompson JA: **A phase II study of desipeptide in refractory metastatic renal cell cancer.** *Clin Genitourin Cancer* 2006, **5**:57-60.
38. Shah MH, Binkley P, Chan K, Xiao J, Arbogast D, Collamore M, et al.: **Cardiotoxicity of histone deacetylase inhibitor desipeptide in patients with metastatic neuroendocrine tumors.** *Clin Cancer Res* 2006, **12**:3997-4003.
39. Rubin EH, Munster PN, van Belle S, Friedman EJ, Patterson JK, Van Dyck K, et al.: **A single supratherapeutic dose of vorinostat (VOR) does not prolong the QTcF interval in patients with advanced cancer [abstract].** *Proceedings of the 100th Annual Meeting of the American Association for Cancer Research* 2009:4560.
40. Acharya MR, Sparreboom A, Venitz J, Figg WD: **Rational development of histone deacetylase inhibitors as anticancer agents: a review.** *Mol Pharmacol* 2005, **68**:917-932.
41. Fantin VR, Richon VM: **Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications.** *Clin Cancer Res* 2007, **13**:7237-7242.
42. Sharma G, Costa L, Gadgil S, Gemmill RM, Drabkin HA: **Combination of sorafenib and vorinostat causes synergistic growth inhibition in carcinomas of the kidney and lung [abstract].** *Proceedings of the 100th Annual Meeting of the American Association for Cancer Research* 2009:1850.
43. Rundall BK, Denlinger CE, Jones DR: **Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer.** *Surgery* 2005, **138**:360-367.
44. Sonnemann J, Gange J, Kumar KS, Muller C, Bader P, Beck JF: **Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines.** *Invest New Drugs* 2005, **23**:99-109.
45. Denlinger CE, Rundall BK, Jones DR: **Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.** *J Thorac Cardiovasc Surg* 2004, **128**:740-748.
46. Rundall BK, Denlinger CE, Jones DR: **Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death.** *Surgery* 2004, **136**:416-425.
47. Campbell RA, Sanchez E, Steinberg J, Share M, Li M, Chen M, et al.: **The potent histone deacetylase inhibitor vorinostat, in combination with melphalan, markedly enhances the anti-myeloma effects of chemotherapy in vitro and in vivo [abstract].** *Proceedings of the 99th Annual Meeting of the American Association for Cancer Research* 2008:733.
48. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, et al.: **Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.** *Proc Natl Acad Sci USA* 2004, **101**:540-545.
49. Pei XY, Dai Y, Grant S: **Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.** *Clin Cancer Res* 2004, **10**:3839-3852.
50. Dai Y, Chen S, Venditti CA, Pei XY, Nguyen TK, Dent P, et al.: **Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate.** *Blood* 2008, **112**:793-804.

51. Dasmahapatra G, Yerram N, Dai Y, Dent P, Grant S: **Synergistic Interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation.** *Clin Cancer Res* 2007, **13**:4280-4290.
52. Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, et al.: **Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.** *Clin Cancer Res* 2006, **12**:5869-5878.
53. Sanchez-Gonzalez B, Yang H, Bueso-Ramos C, Hoshino K, Quintas-Cardama A, Richon VM, et al.: **Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor.** *Blood* 2006, **108**:1174-1182.
54. Gao N, Dai Y, Rahmani M, Dent P, Grant S: **Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.** *Mol Pharmacol* 2004, **66**:956-963.
55. Almenara J, Rosato R, Grant S: **Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).** *Leukemia* 2002, **16**:1331-1343.
56. Nimmanapalli R, Fuino L, Stobaugh C, Richon V, Bhalla K: **Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.** *Blood* 2003, **101**:3236-3239.
57. Yu C, Rahmani M, Almenara J, Subler M, Krystal G, Conrad D, et al.: **Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.** *Cancer Res* 2003, **63**:2118-2126.
58. Rahmani M, Yu C, Dai Y, Reese E, Ahmed W, Dent P, et al.: **Coadministration of the heat shock protein 90 antagonist 17-allylamino-17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.** *Cancer Res* 2003, **63**:8420-8427.
59. Rahmani M, Reese E, Dai Y, Bauer C, Payne SG, Dent P, et al.: **Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.** *Cancer Res* 2005, **65**:2422-2432.
60. Fiskus W, Wang Y, Joshi R, Rao R, Yang Y, Chen J, et al.: **Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells.** *Clin Cancer Res* 2008, **14**:6106-6115.
61. Okabe S, Tauchi T, Kimura S, Maekawa T, Ohyashiki K: **The Analysis of HDAC Inhibitor, Vorinostat Efficacy against Wild Type and BCR-ABL Mutant Positive Leukemia Cells in Monotherapy and in Combination with a Pan-Aurora Kinase Inhibitor, MK-0457 [abstract].** *Blood (ASH Annual Meeting Abstracts)* 2008, **112**:5025.
62. Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andbacka RH, Dunner K Jr, et al.: **Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.** *Cancer Res* 2006, **66**:3773-3781.
63. Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang SM, Harari PM: **Modulation of radiation response by histone deacetylase inhibition.** *Int J Radiat Oncol Biol Phys* 2005, **62**:223-229.
64. Munshi A, Tanaka T, Hobbs ML, Tucker SL, Richon VM, Meyn RE: **Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of {gamma}-H2AX foci.** *Mol Cancer Ther* 2006, **5**:1967-1974.
65. Sonnemann J, Kumar KS, Heesch S, Muller C, Hartwig C, Maass M, et al.: **Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.** *Int J Oncol* 2006, **28**:755-766.
66. Zhang Y, Jung M, Dritschilo A: **Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors.** *Radiat Res* 2004, **161**:667-674.
67. **Clinical trials.gov** [<http://clinicaltrials.gov/>]
68. Ramalingam SS, Parise RA, Ramanathan RK, Lagattuta TF, Musguire LA, Stoller RG, et al.: **Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.** *Clin Cancer Res* 2007, **13**:3605-3610.
69. Wen PY, Puduvalli V, Kuhn J, Reid J, Cloughesy T, Yung WA, et al.: **Phase I study of vorinostat (suberoylanilide hydroxamic acid) in combination with temozolomide (TMZ) in patients with malignant gliomas (NABTC 04-03) [abstract].** *J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part 1* 2007, **25**:2039.
70. Chen L, Vogelzang NJ, Blumenschein G, Robert F, Pluda JM, Frankel SR, et al.: **Phase I trial of vorinostat (V) in combination with pemetrexed (Pem) and cisplatin (CDDP) in patients with advanced cancer [abstract].** *J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part 1* 2007, **25**:18088.
71. Daud A, Schmitt M, Marchion D, Bicauc E, Minton S, Egorin M, et al.: **Phase I trial of a sequence-specific combination of the HDAC inhibitor, vorinostat (SAHA) followed by doxorubicin in advanced solid tumor malignancies [abstract].** *J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part 1* 2007, **25**:3502.
72. Schelman VWR, Kolesar J, Schell K, Marnocha R, Eickhoff J, Alberti D, et al.: **A phase I study of vorinostat in combination with bortezomib in refractory solid tumors [abstract].** *J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part 1* 2007, **25**:3573.
73. Tang P, Oza A, Townsley C, Siu L, Pond G, Sarveswaran P, et al.: **A phase I study of vorinostat (VOR) in combination with capcitabine (CAP) in patients (pts) with advanced solid tumors [abstract].** *J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part 1* 2007, **25**:3576.
74. Fakhri MG, Pendyala L, Fetterly G, Toth K, Zwiebel JA, Espinoza-Delgado I, et al.: **A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer.** *Clin Cancer Res* 2009, **15**:3189-3195.
75. Kelly K, Crowley J, Bunn PA Jr, Presant CA, Grevstad PK, Moinpour CM, et al.: **Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial.** *J Clin Oncol* 2001, **19**:3210-3218.
76. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al.: **Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.** *N Engl J Med* 2006, **355**:2542-2550.
77. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al.: **Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.** *N Engl J Med* 2002, **346**:92-98.
78. Badros A, Philip S, Nlesvizky R, Goloubeva O, Zweibel J, Wright J, et al.: **Phase I trial of vorinostat plus bortezomib (bort) in relapsed and refractory multiple myeloma (MM) patients (pts) [abstract].** *Haematologica* 2008, **93**:0642.
79. Weber DM, Badros A, Jagannath S, Siegel D, Richon V, Rizvi S, et al.: **Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: early clinical experience [abstract].** *Presented at 50th ASCO Annual Meeting & Exposition, December 6-9, San Francisco, USA 2008*:871.
80. Gojo I, Tan MT, Shiozawa K, Nakanishi T, Burger AM, Burgess CL, et al.: **Phase I trial of vorinostat combined with cytarabine and etoposide in patients (pts) with advanced acute leukemia and high-risk myelodysplastic syndromes [abstract].** *Blood (ASH Annual Meeting Abstracts)* 2008, **112**:4011.
81. Grant S, Kolla S, Sirulnik LA, Shapiro G, Supko J, Cooper B, et al.: **Phase I trial of vorinostat (SAHA) in combination with alvocidib (flavopiridol) in patients with relapsed, refractory or (selected) poor prognosis acute leukemia or refractory anemia with excess blasts-2 (RAEB-2) [abstract].** *Blood (ASH Annual Meeting Abstracts)* 2008, **112**:2986.
82. Kadia TM, Ferrajoli A, Ravandi F, Cortes J, Thomas D, Wierda W, et al.: **A Phase I study of the combination of the histone deacetylase inhibitor vorinostat with idarubicin in advanced acute leukemia. [abstract].** *Blood (ASH Annual Meeting Abstracts)* 2007, **110**:1842.
83. Kirschbaum M, Gojo I, Goldberg SL, Kujawski L, Atallah E, Marks P, et al.: **Phase I study of vorinostat in combination with decitabine in patients with relapsed or newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome [abstract].**

Presented at 50th ASH Annual Meeting & Exposition, December 6–9, San Francisco, USA 2008:3651.

84. Ravandi F, Faderl S, Thomas D, Burger J, Koller C, Garcia-Manero G, et al.: **Phase I study of suberoylanilide hydroxamic acid (SAHA) and decitabine in patients with relapsed, refractory or poor prognosis leukemia. [abstract].** *Blood (ASH Annual Meeting Abstracts)* 2007, **110**:897.
85. Silverman LR, Verma A, Odchimar-Reissig R, LeBlanc A, Najfeld V, Gabrilove J, et al.: **A phase I trial of the epigenetic modulators vorinostat, in combination with azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): a study of the New York Cancer Consortium [abstract].** *Blood (ASH Annual Meeting Abstracts)* 2008, **112**:3656.
86. Yee KWL, Minden MD, Brandwein J, Schimmer A, Schuh A, Gupta V, et al.: **A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia (AML). [abstract].** *Blood (ASH Annual Meeting Abstracts)* 2007, **110**:908.
87. Siegel D, Weber DM, Mitsiades CS, Dimopoulos MA, Harousseau JL, Rizvi S, et al.: **Combined vorinostat, lenalidomide and dexamethasone therapy in patients with relapsed or refractory multiple myeloma: a Phase I study [abstract].** *Haematologica* 2009, **94**(Suppl 2):0387.

Publish with **BioMed Central** and every scientist can read your work free of charge

*"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."*

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

